Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Kovina Therapeutics General Information
Kovina Therapeutics is developing first-in-class small molecule antiviral therapies that selectively target and inactivate a key HPV protein. Their approach aims to kill infected cells, providing a non-surgical treatment option for both pre-cancerous lesions and established cancers caused by HPV. The company is currently at the preclinical stage with no human clinical results reported yet.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Indianapolis, Indiana
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Indiana University (IU): scientific research collaboration; IP licensed from IU
Kovina Therapeutics Funding
No funding data available
To view Kovina Therapeutics's complete valuation and funding history, request access »